Vitexin enhances BMP9-induced osteogenic differentiation in mesenchymal stem cells (MSCs)
Session Number
Project ID: MEDH 19
Advisor(s)
Dr. Tong-Chuan He; University of Chicago
Dr. Meng Zhang; University of Chicago
Discipline
Medical and Health Sciences
Start Date
22-4-2020 9:45 AM
End Date
22-4-2020 10:00 AM
Workshop Synopsis
Mesenchymal stem cells (MSCs) are multipotent stromal cells that have the potential to differentiate into a variety of cell types, including osteoblasts (bone cells). MSCs are thus applicable in bone regeneration, which can be used to treat bone disorders and injuries and potentially even bone cancer. To better understand the process of MSC differentiation, we investigated the effect of vitexin on the osteogenesis induced by bone morphogenetic protein-9 (BMP-9) in MSCs. We detected osteogenic differentiation by studying Alkaline Phosphatase (ALP) activity and the Alizarin Red S staining of mineralized matrices when iMAD cells were treated with BMP9 and/or Vitexin. Then, the gene expression of the osteogenic markers was detected by quantitative reverse transcription polymerase chain reaction (qPCR). We found that BMP9 and Vitexin increased the activity of early osteogenic differentiation marker ALP. The activities are more pronounced when treated by both BMP9 and Vitexin than when treated by BMP9 or Vitexin alone. These results indicate that Vitexin potentiates the osteogenesis induced by BMP9 in MSCs and is, therefore, a promising method in bone tissue engineering.
Vitexin enhances BMP9-induced osteogenic differentiation in mesenchymal stem cells (MSCs)